CRISPR Therapeutics AG (NASDAQ:CRSP) shares are trading higher Monday after Morgan Stanley maintained the company with an Underweight rating and lowered the price target.
What To Know:
On Monday, Morgan Stanley analyst Terence Flynn maintained CRISPR Therapeutics with an Underweight and lowered the price target from $43 to $42.
Last Tuesday, RBC Capital analyst Luca Issi maintains CRISPR Therapeutics with a Sector Perform and lowered the price target from $55 to $50.
Also, Needham analyst Gil Blum maintained CRISPR Therapeutics with a Buy and lowered the price target from $88 to $85.
CRISPR Therapeutics reported third-quarter losses of $1.41 per share last Monday, beating the analyst consensus estimate of loss of $1.96 per share.
CRISPR Therapeutics shares have attracted attention from retail investors as well as short-sellers. The stock is one of the top trending tickers on Yahoo Finance, and 17.72% of available CRSP shares are being sold short, according to data from Benzinga Pro.
Related News: What’s Going On With Tivic Health Systems Inc Stock?
CRSP Price Action: According to Benzinga Pro, CRISPR Therapeutics shares are down 7% at $49.39 at the time of publication.
Image: Arek Socha from Pixabay
